TP53 and RET may serve as biomarkers of prognostic evaluation and targeted therapy in hepatocellular carcinoma

Mostrar otras versiones (1)

Hepatocellular carcinoma (HCC) is the most common malignancy of the liver. Genomic analysis is conducted to identify genetic alterations in driver genes which are all druggable targets for cancer therapy. In the present study, we performed an exome sequencing of 45 driver genes in 100 paired samples...

Descripción completa

Detalles Bibliográficos
Autores principales: Ye, Song, Zhao, Xin-Yi, Hu, Xiao-Ge, Li, Tang, Xu, Qiu-Ran, Yang, Huan-Ming, Huang, Dong-Sheng, Yang, Liu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2017
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5367355/
https://www.ncbi.nlm.nih.gov/pubmed/28350084
http://dx.doi.org/10.3892/or.2017.5494

Ejemplares similares

Ejemplares similares